Literature DB >> 35450312

Incidence and Prevalence of Skin Cancers in South Korea from 2008 to 2016: A Nation-Wide Population Based Study.

Kyungduck Park1, Jung Min Bae2, Kee Yang Chung3, Sook Jung Yun4, Soo Hong Seo5, Hyo Hyun Ahn5, Dong-Youn Lee6, Heesu Kim7, Uri Sohn8, Byung Cheol Park8.   

Abstract

Background: In South Korea, there have been few nationwide epidemiologic studies about premalignant actinic keratosis (AK), squamous cell carcinoma in situ (Bowen's disease), nonmelanoma skin cancer (NMSC), malignant melanoma of the skin (MM), Kaposi's sarcoma (KS), connective and soft tissue cancers, or mycosis fungoides (MF). Objective: Using a nationwide population-based study, we attempted to measure the incidence and the prevalence of the above-mentioned tumors in South Korea.
Methods: The database we used included all claims in the Korean National Health Insurance program and the Korean Medical Aid program from 2008 to 2016. The International Classification of Diseases, 10th revision (ICD-10) was used to record diagnoses in this database. This data included AK, Bowen's disease, NMSC, MM, KS, connective and soft tissue cancers, and MF.
Results: The age-standardized incidence and prevalence rate of AK, Bowen's disease, NMSC, MM, KS, connective and soft tissue cancers, as well as MF increased during the periods we investigated. The incidence and prevalence rate of AK and NMSC have increased two- to three-fold. In the case of Bowen's disease, MM, KS, connective and soft tissue cancers, or MF, we observed no significant tendency in age-standardized incidence or prevalence.
Conclusion: We confirmed that the age-standardized incidence and prevalence rates of NMSC and AK tended to increase. These results might contribute to developing preventive and therapeutic strategies for skin cancers and may become a source for further studies.
Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology.

Entities:  

Keywords:  Incidence; Korea; Prevalence; Skin neoplasms

Year:  2022        PMID: 35450312      PMCID: PMC8989896          DOI: 10.5021/ad.2022.34.2.105

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


INTRODUCTION

Skin cancer is one of the most commonly occurring cancers, and understanding the incidence of this trend is crucial. This is important for planning prevention and treatment strategies and allocating medical resources. The incidence and trends of nonmelanoma skin cancer (NMSC) and cutaneous melanoma have been relatively well reported in western countries123456, and there have been two Korean studies78 about these. However in South Korea, there have been few nationwide epidemiologic studies about Kaposi’s sarcoma (KS), connective and soft tissue cancers, or cutaneous T-cell lymphoma78. Korea has the National Health Insurance (NHI) System, and it is relatively easy to obtain nationwide data, although some diseases have not been clearly classified based on the system. In order to establish appropriate policy about skin cancer and research the problem, we analyzed the incidence and prevalence rates of the above skin tumors in Korea.

MATERIALS AND METHODS

We analyzed skin cancer data from NHI System Claims Database from 2008 to 2016. This database included all claims provided by the Korean NHI program and the Korean Medical Aid program during the given period. The International Classification of Diseases, 10th revision (ICD-10) was used to record diagnoses in the database. Our definition for malignant melanoma (MM) is based on the ICD-10 code series from C43.0 to C43.9 and D03. For NMSC, we used the C44.0-C44.9 ICD-10 codes, which are defined as other and unspecified malignant skin neoplasms, depending upon their location. KS was designated as ICD-10 codes C46.0 to C46.9 according to body sites, soft tissue cancer as C49.0 to C49.9, mycosis fungoides (MF) as C84.0, Bowen’s disease as D04.0 to D04.9, and actinic keratosis (AK) as L57.0. The data included details regarding patient age and sex, as well as information related to diagnosis and treatment. We investigated the age-standardized incidence and prevalence rates. Incidence is defined in terms of the occurrence of new disease cases in a population over a specified period of time. Prevalence is the proportion of patients in the population who have a particular disease at a particular time or over a specified period of time. Age standardization is a way to adjust the crude rate to account for differences in population age structures when comparing crude rates for different periods of time, geographical areas, or subgroups of the population. The age-standardized rate of a population is the summary rate it would have if it had a standard age structure. Age-standardized incidence and prevalence rates were calculated as the sum of weighted incidence rate for each five-year age group using Segi’s world standard population. We also checked age-specific incidence rates for representative skin cancers. Age-specific incidence rates equal the total number of new cases limited to a particular age group, which is divided by the at-risk population for that category. This study is the exemption of IRB.

RESULTS

Age-standardized incidence rate

In general, the incidence rate of all the skin cancers investigated in this study tended to increase from 2008 to 2016. The incidence rate of AK and NMSC increased significantly, from 6.86 to 17.96 and 6.32 to 10.11 per 100,000 person-years. However, Bowen’s disease, MM, KS, connective and soft tissue cancers, and MF have not increased significantly (Table 1).
Table 1

Age-standardized incidence rate of representative skin cancers

Variable200820092010201120122013201420152016
Actinic keratosis6.867.678.0410.3911.7313.2015.0216.6017.96
Bowen’s disease2.121.862.131.891.891.982.042.092.51
Non melanoma skin cancer6.326.446.667.517.838.208.829.1510.11
Malignant melanoma2.271.992.092.242.292.242.592.392.63
Kaposi’s sarcoma0.200.170.250.260.230.240.230.260.28
Connective tissue tumor2.552.432.522.542.612.562.722.872.88
Mycosis fungoides0.170.200.160.190.160.160.170.170.24

Age-standardized incidence rate is expressed in 100,000 person-years.

Age-standardized prevalence rate

In this study, the incidence and prevalence rates for all skin cancers have increased proportionally and continuously from 2008. The AK and NMSC prevalence rates have especially increased sharply, from 7.52 to 22.93 and 9.15 to 19.20 per 100,000 person-years. The prevalence rates of MM, KS, MF, and connective tissue tumor have tended to increase, although their incidence rates have not increased very much (Table 2).
Table 2

Age-standardized prevalence rate of representative skin cancers

Variable200820092010201120122013201420152016
Actinic keratosis7.528.769.6412.2714.2816.2918.5320.8022.93
Bowen’s disease2.472.272.662.482.552.762.983.113.67
Non-melanoma skin cancer9.1510.3311.1112.5413.6814.7016.1317.4219.20
Malignant melanoma3.793.814.104.424.694.875.415.405.82
Kaposi’s sarcoma0.350.340.420.460.430.460.480.500.56
Connective tissue tumor6.096.517.087.427.808.018.508.999.51
Mycosis fungoides0.390.490.470.510.530.550.610.640.72

Age-standardized prevalence rate is expressed in 100,000 person-years.

Age-specific incidence of representative skin cancers

The overall incidence rate of all skin cancers in this study has tended to increase with age, with a peak incidence age being in the 70s in AK, Bowen’s disease, NMSC, but in the 60s in MM and connective tissue tumors (Table 3).
Table 3

Age-specific incidence of representative skin cancers

Age (yr)Actinic keratosisBowen’s diseaseNon-melanoma skin cancerMalignant melanomaKaposi’s sarcomaConnective tissue tumorMycosis fungoides
0~90.900.040.070.060.000.130.01
10~191.140.060.090.100.000.190.03
20~290.680.140.190.150.000.250.05
30~390.570.130.300.190.010.280.04
40~490.720.140.520.240.010.340.04
50~591.210.220.940.340.010.430.04
60~692.120.421.690.470.010.490.04
70~792.770.492.170.450.020.360.03
>801.800.411.930.310.010.180.01
Total11.942.067.892.300.072.630.30

Age-specific incidence is expressed in 100,000 person-years (2008~2016). Nonmelanoma skin cancer and Bowen’s disease incidence rates tend to increase with age.

DISCUSSION

Throughout this study, we identified the prevalence and incidence of AK, Bowen’s disease, NMSC, MM, KS, connective and soft tissue cancers, and MF in South Korea. In particular, the incidence and prevalence of AK, KS, connective and soft tissue cancers, or MF are not as well-known as compared to NMSC or MM in other countries59. The age-standardized incidence and prevalence rate of all skin cancers included in this study has tended to increase. The reason for this phenomenon is probably the low mortality rate of NMSC and the change to an aging society in Korea. We especially confirmed that age-standardized incidence and prevalence rates of NMSC and AK tended to increase sharply as compared to other cancers. It is well known that AK, a premalignant lesion, usually progresses to squamous cell carcinoma (SCC) through SCC in situ (Bowen’s disease). Therefore, it is reasonable to assume that the incidence of Bowen’s disease also increases. However, we could not find any tendency in the incidence rate of Bowen’s disease. This might be because of this study’s short observation time of eight years, because it may take a long time for AK to change into Bowen’s disease. Alternatively, Bowen’s disease often occurs in areas not exposed to sunlight, and the incidence of Bowen’s disease may not necessarily correlate with the incidence of AK. In two previous Korean studies78, the incidence rate of NMSC and MM increased. However, the increase is usually higher in NMSC than in MM. The present study also found that the incidence rate of NMSC was higher than MM during the examination period. According to reports from western countries, such as the Netherlands and Sweden1011, the incidence of UV-related skin tumors (such as basal cell carcinoma [BCC], SCC, or MM) increased significantly and more steeply than did those of other skin malignancies. In Korean studies of incidence rates by age78, the incidence of melanoma, BCC, and SCC increased the most in those over 80 years of age. The peak age of AK, Bowen’s disease, and BCC was greatest among those who are 61~80 years of age. In the present study, age-specific incidence rates for NMSC and AK is in the 70s. Thus, the incidence trend for NMSC is similar to the previous study. However, the peak incidence age for MM is in the 60s, unlike the previous Korean study8. Melanoma has been known to be a highly aggressive skin cancer with a higher disease-specific death rate than SCC or BCC. Thus, it is postulated that its peak incidence might be lower than NMSC, including SCC or BCC. On the other hand, the increased rate of incidence in other cancers except NMSC and AK was not significant. In the Netherlands data10, no significant incidence increases were observed for lymphomatous, appendageal, fibromatous, or myomatous carcinomas during 1989~2005. Spanish data also shows12 that there was no significant increase in the incidence of dermatofibrosarcoma protuberans, adnexal, or skin appendage neoplasm over the entire period, even when the analysis was done for both sexes, either together or separately. The limitation of this study is that it does not distinguish between BCC and SCC because it is based on the ICD-10 code data, which could not make this distinction. However, these results may have implications for establishing prevention and treatment strategies for skin cancer and may lead to additional research.
  12 in total

1.  Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group.

Authors:  M R Karagas; E R Greenberg; S K Spencer; T A Stukel; L A Mott
Journal:  Int J Cancer       Date:  1999-05-17       Impact factor: 7.396

2.  Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012.

Authors:  Howard W Rogers; Martin A Weinstock; Steven R Feldman; Brett M Coldiron
Journal:  JAMA Dermatol       Date:  2015-10       Impact factor: 10.282

3.  Incidence and Trends of Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma: A Population-Based Study in Olmsted County, Minnesota, 2000 to 2010.

Authors:  John G Muzic; Adam R Schmitt; Adam C Wright; Dema T Alniemi; Adeel S Zubair; Jeannette M Olazagasti Lourido; Ivette M Sosa Seda; Amy L Weaver; Christian L Baum
Journal:  Mayo Clin Proc       Date:  2017-05-15       Impact factor: 7.616

4.  Incidence and trends of cutaneous malignancies in the Netherlands, 1989-2005.

Authors:  Cynthia Holterhues; Esther de Vries; Marieke W Louwman; Senada Koljenović; Tamar Nijsten
Journal:  J Invest Dermatol       Date:  2010-03-25       Impact factor: 8.551

Review 5.  A systematic review of worldwide incidence of nonmelanoma skin cancer.

Authors:  A Lomas; J Leonardi-Bee; F Bath-Hextall
Journal:  Br J Dermatol       Date:  2012-05       Impact factor: 9.302

6.  Nationwide Trends in the Incidence of Melanoma and Non-melanoma Skin Cancers from 1999 to 2014 in South Korea.

Authors:  Chang-Mo Oh; Hyunsoon Cho; Young-Joo Won; Hyun-Joo Kong; Yun Ho Roh; Ki-Heon Jeong; Kyu-Won Jung
Journal:  Cancer Res Treat       Date:  2017-07-14       Impact factor: 4.679

7.  Recent trend in the incidence of premalignant and malignant skin lesions in Korea between 1991 and 2006.

Authors:  Hei Sung Kim; Eun Ah Cho; Jung Min Bae; Dong Soo Yu; Shin Taek Oh; Hoon Kang; Chul Jong Park; Jeong Deuk Lee; Jun Young Lee; Si-Yong Kim; Hyung Ok Kim; Young Min Park
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

8.  Incidence trends of squamous cell and rare skin cancers in the Swedish national cancer registry point to calendar year and age-dependent increases.

Authors:  Shehnaz K Hussain; Jan Sundquist; Kari Hemminki
Journal:  J Invest Dermatol       Date:  2010-01-21       Impact factor: 8.551

9.  Malignant melanoma and nonmelanoma skin cancers in Northrhine-Westphalia, Germany: a patient- vs. diagnosis-based incidence approach.

Authors:  Andreas Stang; Sebastian Ziegler; Ute Büchner; Barbara Ziegler; Karl-Heinz Jöckel; Volker Ziegler
Journal:  Int J Dermatol       Date:  2007-06       Impact factor: 2.736

10.  Incidence trends of keratinocytic skin cancers and melanoma in Israel 2006-11.

Authors:  T Sella; I Goren; V Shalev; H Shapira; J Zandbank; J Rosenblum; M G Kimlin; G Chodick
Journal:  Br J Dermatol       Date:  2014-11-20       Impact factor: 9.302

View more
  1 in total

1.  CD47 Expression in Non-Melanoma Skin Cancers and Its Clinicopathological Implications.

Authors:  Seongsik Bang; Seungyun Jee; Hwangkyu Son; Hyebin Cha; Hosub Park; Jaekyung Myung; Joo Yeon Ko; Hyunsung Kim; Seungsam Paik
Journal:  Diagnostics (Basel)       Date:  2022-07-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.